Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

详细信息    查看全文

• 作者：Bin-Chi Liao ; Chia-Chi Lin ; James Chih-Hsin Yang
• 关键词：Non ; small cell lung cancer ; Afatinib ; EGFR mutation ; Squamous cell carcinoma ; HER2 mutation ; Central nervous system metastasis
• 刊名：Current Oncology Reports
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：19
• 期：1
• 全文大小：
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1534-6269
• 卷排序：19

文摘

Afatinib, a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been approved worldwide as a first-line treatment for advanced non-small cell lung cancer (NSCLC) that harbors activating EGFR mutations. Here, we have reviewed the recent clinical developments in the treatment of lung cancer using afatinib. Emerging data have revealed the overall survival benefit of first-line afatinib therapy in patients with advanced EGFRdel19-positive NSCLC. Phase III studies of afatinib have shown the effectiveness of afatinib as a second-line treatment for advanced lung squamous cell carcinoma, as well as the benefit of continuing afatinib therapy in combination with cytotoxic chemotherapy for advanced NSCLC after the occurrence of disease progression in patients who are receiving afatinib monotherapy. Therapeutic benefits of afatinib have also been reported in studies of patients with central nervous system metastasis and patients with HER2 mutation. The utility of afatinib-based combination therapies is being investigated in ongoing research.